Use of antiviral agents and other measures in an influenza pandemic

Netherlands Journal of Medicine

Volumn 63, Issue 9, 2005, Pages 339-343

  Groeneveld, K ^a   van der Noordaa, J ^b  

^a Health Council of the Netherlands   (Netherlands)

^b Department of Virology ^*  (Netherlands)

Author keywords

Antiviral agents; Influenza; Pandemic; Ring prophylaxis; Risk groups; Treatment

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ADVISORY COMMITTEE; AVIAN INFLUENZA; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH SERVICE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFECTION CONTROL; INFECTION PREVENTION; NETHERLANDS; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VACCINATION; VIRUS INFECTIVITY; VIRUS VIRULENCE;

ACETAMIDES; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; NETHERLANDS; NEURAMINIDASE; OSELTAMIVIR; PRACTICE GUIDELINES; PYRANS; RISK; SIALIC ACIDS; ZANAMIVIR;

EID: 28644440643     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003;362:1733-45.
2. Health Canada. Canadian pandamic influenza plan. 2004. Internet: http://www.hc-sc.gc.ca/pphb-dgspsp/cpip-pclcpi/.
3. Oxford JS. Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Rev Med Virol 2000;10:119-33.
4. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998;178:53-60.
5. Health Council of the Netherlands. Influenza in the Netherlands in 1918 to 1920. Health Council of the Netherlands, 1921.
6. World Health Organization. Avian influenza A (H5N1). Weekly epidemiological record 2004;79:65-76.
7. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, Nguyen VC et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004;350:1179-88.
8. Health Council of the Netherlands. Antiviral agents in an influenza pandemic. The Hague: Health Council of the Netherlands, 2004/05E.
9. Health Council of the Netherlands. Use of antiviral agents and other measures in an influenza pandemic. The Hague: Health Council of the Netherlands, 2005/05E.
10. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235.
11. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003;7:iii-xiii, 1.
12. Stohr K. Preventing and treating influenza. BMJ 2003;326:1223-4.
13. Oxford JS, Novelli P, Sefton A, Lambkin R. New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. Antivir Chem Chemother 2002;13:205-17.
14. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:748-54.
15. Van Essen GA, Sorgedrager YCG, Salemink GW, Govaert ThME, van den Hoogen JPH, van der Laan JR. NHG-standaard influenza en influenzavaccinatie. In: Thomas S, Geijer RMM, van der Laan JR, Wiersma Tj, editors. NHG-standaarden voor de huisarts. Utrecht: Bunge, 1996:179-83.
16. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000;160:3243-7.
17. Kretzschmar M, van den Hof S, Wallinga J, van Wijngaarden J. Ring vaccination and smallpox control. Emerg Infect Dis 2004;10:832-41.
18. Balicer RD, Huerta M, Grotto I. Tackling the next influenza pandemic. BMJ 2004;328:1391-2.
19. Wallinga J, Mylius S. Verwachtingen voor het verloop van een influenza pandemie met en zonder interventiestrategieën. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu, 2004/1.
20. Longini IM, Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004;159:623-33.
21. Longini IM, Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, et al. Containing pandemic influenza at the source. Science 2005;309:1083-7.
22. Jordan WS, Jr, Denny FW, Jr, Badger GF, et al. A study of illness in a group of Cleveland families. XVII. The occurrence of Asian influenza. Am J Hyg 1958;68:190-212.
23. Miller DL, Pereira MS, Clarke M. Epidemiology of the Hong Kong-68 variant of influenza A2 in Britain. Br Med J 1971;1:475-9.
24. Potter CW. Chronicle of influenza pandemics. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. London: Blackwell Scientific Publications, 1998:3-18.
25. Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003;21:1762-8.
26. Health Council of the Netherlands. Vaccination policies in case of an influenza pandemic. The Hague, 2000/01.
27. Harling R, Hayward A, Watson JM. Implications of the incidence of influenza-like illness in nursing homes for influenza chemoprophylaxis: descriptive study. BMJ 2004;329:663-4.
28. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364:759-65.
29. Moscona A. Oseltamivir-resistant influenza? Lancet 2004;364:733-4.0